Educational reference only. Not medical advice. Consult a healthcare provider before starting any protocol.
CJC-1295
CJC-1295 (with and without DAC)
What it is
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH). It has been studied in the context of growth hormone secretion and is available in two forms: with Drug Affinity Complex (DAC) for extended duration, and without DAC (also called Modified GRF 1-29) for shorter activity. It is discussed in communities focused on growth hormone optimization, body composition, and recovery.
Community-reported ranges
Ranges sourced from community forums and published preclinical literature. Not dosing guidance.
Reported dose range
100–300 mcg
Estimated half-life
~30 minutes (no DAC) / ~8 days (with DAC)
Source: Published human pharmacokinetic data
Reported cycle length
8–12 weeks on
4–8 weeks off
Route
Subcutaneous
Common vial sizes
2mg, 5mg
Reported timing
Before bed or AM on empty stomach
Reported frequency
1x daily (no DAC) or 1–2x per week (with DAC)
Frequently discussed alongside
Based on community forum discussions. Not a recommendation to combine compounds.
Published research
CJC-1295 has been studied in human clinical trials evaluating its effects on growth hormone and IGF-1 levels. Published pharmacokinetic studies have characterized its half-life in both DAC and non-DAC forms. Research has examined its potential in the context of growth hormone deficiency and body composition. The DAC form demonstrated sustained GH elevation over several days in published studies. Community discussion often focuses on combining CJC-1295 (no DAC) with growth hormone-releasing peptides such as ipamorelin.
Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.
Journal of Clinical Endocrinology & Metabolism
Ionescu M, Bhatt DL, et al. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
Journal of Clinical Endocrinology & Metabolism
Reported side effects
From community self-reports. Not from controlled studies.
Community self-reports include: flushing, water retention, tingling or numbness in extremities, increased hunger, and fatigue. Some users report vivid dreams. These are anecdotal reports from community forums, not findings from controlled clinical studies.
Regulatory status
FDA (United States)
Not approved for any indication.
Health Canada
Not authorized as a therapeutic product. No DIN assigned.
WADA (Competitive Athletes)
Prohibited substance for competitive athletes (growth hormone secretagogue).